Glenmark Pharmaceuticals Ltd.

₹1962.6

Glenmark Pharmaceuticals Ltd.

Add Alert
Add Watchlist

₹1962.6

₹1962.6

-8.6 (-0.44%) - 7 Oct 2025 04:21 PM

About Company

Glenmark Pharmaceuticals Limited is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.

Market Cap. ₹ 55,385 Cr.
52 Week - High/Low ₹ 2,285/1,276
P/E Ratio 37.25
P/B Ratio 2.26
Enterprise Value ₹ 60,272 Cr.
ROE % 6.78
RSI Value 40.47
EMA 50 1985.44
EMA 200 1733.32
Market Cap. ₹ 55,385 Cr.
52 Week - High/Low ₹ 2,285/1,276
P/E Ratio 73.51
P/B Ratio 6.26
Enterprise Value ₹ 53,789 Cr.
ROE % 12.56
RSI Value 40.47
EMA 50 1985.44
EMA 200 1733.32

Valuation

Calculators

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Insight market
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.